Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

Garrido-Castro AC, Goel S.

Curr Breast Cancer Rep. 2017 Mar;9(1):26-33. doi: 10.1007/s12609-017-0232-0. Epub 2017 Feb 1.

PMID:
28479958
2.

Progress with palbociclib in breast cancer: latest evidence and clinical considerations.

Rocca A, Schirone A, Maltoni R, Bravaccini S, Cecconetto L, Farolfi A, Bronte G, Andreis D.

Ther Adv Med Oncol. 2017 Feb;9(2):83-105. doi: 10.1177/1758834016677961. Epub 2016 Nov 21. Review.

3.

Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.

Bernhardt SM, Dasari P, Walsh D, Townsend AR, Price TJ, Ingman WV.

Front Oncol. 2016 Nov 14;6:241. eCollection 2016. Review.

4.

Overexpression of caspase 7 is ERα dependent to affect proliferation and cell growth in breast cancer cells by targeting p21(Cip).

Chaudhary S, Madhukrishna B, Adhya AK, Keshari S, Mishra SK.

Oncogenesis. 2016 Apr 18;5:e219. doi: 10.1038/oncsis.2016.12.

5.

PELP1: Structure, biological function and clinical significance.

Sareddy GR, Vadlamudi RK.

Gene. 2016 Jul 1;585(1):128-134. doi: 10.1016/j.gene.2016.03.017. Epub 2016 Mar 18. Review.

PMID:
26997260
6.

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.

Finn RS, Aleshin A, Slamon DJ.

Breast Cancer Res. 2016 Feb 9;18(1):17. doi: 10.1186/s13058-015-0661-5. Review.

7.

Cell cycle networks link gene expression dysregulation, mutation, and brain maldevelopment in autistic toddlers.

Pramparo T, Lombardo MV, Campbell K, Barnes CC, Marinero S, Solso S, Young J, Mayo M, Dale A, Ahrens-Barbeau C, Murray SS, Lopez L, Lewis N, Pierce K, Courchesne E.

Mol Syst Biol. 2015 Dec 14;11(12):841. doi: 10.15252/msb.20156108.

8.

FERAL: network-based classifier with application to breast cancer outcome prediction.

Allahyar A, de Ridder J.

Bioinformatics. 2015 Jun 15;31(12):i311-9. doi: 10.1093/bioinformatics/btv255.

9.

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.

López-Knowles E, Wilkerson PM, Ribas R, Anderson H, Mackay A, Ghazoui Z, Rani A, Osin P, Nerurkar A, Renshaw L, Larionov A, Miller WR, Dixon JM, Reis-Filho JS, Dunbier AK, Martin LA, Dowsett M.

Breast Cancer Res. 2015 Mar 11;17:35. doi: 10.1186/s13058-015-0532-0.

10.

PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.

Cortez V, Samayoa C, Zamora A, Martinez L, Tekmal RR, Vadlamudi RK.

Cancer Res. 2014 Dec 15;74(24):7395-405. doi: 10.1158/0008-5472.CAN-14-0993. Epub 2014 Nov 6.

11.

Curcumin: a potential candidate in prevention of cancer via modulation of molecular pathways.

Rahmani AH, Al Zohairy MA, Aly SM, Khan MA.

Biomed Res Int. 2014;2014:761608. doi: 10.1155/2014/761608. Epub 2014 Sep 10. Review.

12.

Co-treatment of mouse antral follicles with 17β-estradiol interferes with mono-2-ethylhexyl phthalate (MEHP)-induced atresia and altered apoptosis gene expression.

Craig ZR, Singh J, Gupta RK, Flaws JA.

Reprod Toxicol. 2014 Jun;45:45-51. doi: 10.1016/j.reprotox.2014.01.002. Epub 2014 Jan 9.

13.

Odontogenic ameloblast-associated protein (ODAM) inhibits growth and migration of human melanoma cells and elicits PTEN elevation and inactivation of PI3K/AKT signaling.

Foster JS, Fish LM, Phipps JE, Bruker CT, Lewis JM, Bell JL, Solomon A, Kestler DP.

BMC Cancer. 2013 May 7;13:227. doi: 10.1186/1471-2407-13-227.

14.

Derailed estrogen signaling and breast cancer: an authentic couple.

Manavathi B, Dey O, Gajulapalli VN, Bhatia RS, Bugide S, Kumar R.

Endocr Rev. 2013 Feb;34(1):1-32. doi: 10.1210/er.2011-1057. Epub 2012 Sep 4. Review.

15.

Stable inhibition of specific estrogen receptor α (ERα) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells.

Huderson BP, Duplessis TT, Williams CC, Seger HC, Marsden CG, Pouey KJ, Hill SM, Rowan BG.

Endocrinology. 2012 Sep;153(9):4144-59. doi: 10.1210/en.2011-2001. Epub 2012 Jun 25.

16.

In vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer.

Pais A, Gunanathan C, Margalit R, Biton IE, Yosepovich A, Milstein D, Degani H.

Cancer Res. 2011 Dec 15;71(24):7387-97. doi: 10.1158/0008-5472.CAN-11-1226. Epub 2011 Oct 31.

17.

A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma.

Peng CH, Liao CT, Peng SC, Chen YJ, Cheng AJ, Juang JL, Tsai CY, Chen TC, Chuang YJ, Tang CY, Hsieh WP, Yen TC.

PLoS One. 2011;6(8):e23452. doi: 10.1371/journal.pone.0023452. Epub 2011 Aug 11.

18.

ODAM Expression Inhibits Human Breast Cancer Tumorigenesis.

Kestler DP, Foster JS, Bruker CT, Prenshaw JW, Kennel SJ, Wall JS, Weiss DT, Solomon A.

Breast Cancer (Auckl). 2011;5:73-85. doi: 10.4137/BCBCR.S6859. Epub 2011 Apr 28.

19.

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.

Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, Clarke R, Knudsen ES.

Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.

20.

Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells.

Rodriguez BA, Weng YI, Liu TM, Zuo T, Hsu PY, Lin CH, Cheng AL, Cui H, Yan PS, Huang TH.

Carcinogenesis. 2011 Jun;32(6):812-21. doi: 10.1093/carcin/bgr017. Epub 2011 Feb 8.

Supplemental Content

Support Center